TX-MAVENIR
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud infrastructure and transforms the way the world connects, today announced its Business Support System (BSS) solution called Mavenir Digital Enablement (MDE) platform. The MDE Platform enables Communications Service Providers (CSPs) to quickly and easily build new digital offerings through a simplified graphical service experience creator. MDE can be deployed either as a standalone BSS or as an overlay on the CSP’s legacy BSS.
This solution uses a proven Microservices, API-first, Cloud-Native, Headless (MACH) architecture that is aligned with TM Forum’s Open Digital Architecture (ODA) and OpenAPIs . Its low/no-code UI enables agile experience creation. With a unified product catalog, MDE lets CSPs easily develop and deploy new services, speeding both time to market and time to revenue. The solution also provides tools for consolidation and transformation of network usage and non-usage data, which generates insightful information to help deliver hyper-personalized services and offerings through an omnichannel experience.
Mavenir’s unique technology enables a “composable” BSS architecture so CSPs can design their own BSS solution by assembling the right mix of microservices from the MDE library. It is designed to help CSPs innovate fearlessly without being restricted by the inflexibility of legacy BSS or IT systems. It also enables them to leverage their existing BSS/IT infrastructure by deploying the MDE Marketplace as an overlay solution. Use cases include:
- Delivering greenfield MNO services
- Enabling a digital marketplace for bundling CSP services with partner services to generate new revenue streams
- Introducing a sub-brand in response to digital attacker brands or to address a niche segment of the market
- Launching a new MVNO service by utilizing the MDE BSS as a Mobile Virtual Network Enabler (MVNE)
The MDE BSS platform can quickly and easily be deployed as an adjunct solution to launch new business services such as:
- 5G FWA/eMBB/AR/VR services
- IoT services for B2C/B2B/B2B2X customers
- Connectivity bundles for B2B customers
- Unified communication (UCC) and contact center for B2B customers
- Rich Business Messaging using RCS for B2B customers
“Mavenir’s MDE platform enables CSPs to deliver the promise of 5G and speed up the return on their 5G investments by eliminating perpetually slow processes and the barriers of cost and time from legacy BSS,” said BG Kumar, President Communications Services at Mavenir. “Through its open APIs, MDE easily integrates with existing IT or BSS systems and can run as an overlay solution, giving CSPs the option to escape existing vendor lock-in and freedom from development limitations on legacy IT systems.”
The solution is currently deployed with various CSPs in APAC, Europe, and the Americas.
Supporting documents:
- MDE Webpage
- MDE Solutions Brief
- MDE White Paper: Five Steps to a Digital Telecom Marketplace
- MDE Video
- Mavenir's Cloudified Portfolio Press Release
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005238/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom